Introduction {#s1}
============

Lutembacher syndrome is a rare combination of congenital ostium secundum atrial septal defect (ASD) and acquired mitral valve stenosis (MVS) with female predominance and unfavorable long-term progression \[[@R01]-[@R03]\]. Although open heart surgery is still considered the treatment of choice to fix the both conditions at the same time, it is associated with surgical complications, long hospital stay, sternotomy, skin scar, psychosocial effect and higher surgical risk if reoperation for mitral valve restenosis is necessary later. Because the percutaneous treatment of MVS using balloon valvuloplasty and percutaneous closure of ASD using atrial septal occluders are widely considered safe and efficacious \[[@R04]-[@R11]\], these procedures can be utilized as an alternative therapy for the combined conditions in Lutembacher syndrome.

Case Report {#s2}
===========

We present a case of 59-year-old female who was diagnosed with Lutembacher syndrome 3 years ago but refused to have cardiac surgery and was being maneged with medicine. She hospitalized because of dyspnea and palpitation that was increased gradually and unberable recently. The patient's exercise tolerance was reduced and the New York Heart Association (NYHA) functional class increased from class II at the last check-up 30 days before to class IV at this hospitalization. Phisical examination showed loud first heart sound, fixed and wide splitting of the second heart sound and mid-diastolic rumbling murmur at the apex. Echocardiography (ECG) showed atrial fibrillation, right atrial hypertrophy, right ventricular hypertrophy and incomplete right bundle branch block. The cardiothoracic ratio was 0.65 on chest radiography. ECG showed a 22-mm secundum ASD with left to right shunt and good surrounding rims. There was also severe MVS with the mitral valve area (MVA) of 0.88 cm^2^ by planimetry, Wilkin score of 7/16, mean transmitral gradient of 15 mm Hg and insignificant mitral regurgitation. The left atrium, right atrium and right ventricle were dilated and no thrombus was detected. On catheterization, the Qp/Qs ratio was 4.6, the mean pulmonary arterial pressure was 36 mm Hg, the mean left atrial pressure was 22 mm Hg and the mean transmitral gradient was 14 mm Hg. Because the patient refused to have cardiac surgery, the symptoms were getting worse with optimal medication, and both the ASD and MVS appeared to be suitable for transcatheter treatment, we planned to perform mitral valvuloplasty and ASD closure in the same setting after explaining the benefits, risks and obtaining patient consent form.

The transcatheter mitral valvuloplasty and ASD closure procedures were performed with preparations, devices and approaches that were described in the literature \[[@R08], [@R9], [@R12]-[@R14]\]. The mitral valvuloplasty was done first with a 24-mm Inoue balloon (Toray Medical Co., Japan) through the existing ASD ([Fig. 1](#F1){ref-type="fig"}). After valvuloplasty, the MVA was 1.92 cm^2^, the mean left atrial pressure was 11 mm Hg, the mean transmitral gradient was 6 mm Hg and the Qp/Qs ratio was 2.8:1. Subsequently, the ASD was successfully closed using a 26-mm Cocoon Septal Occluder (Vascular Innovations Co., Thailand) without complication ([Fig. 2](#F2){ref-type="fig"}). The echocardiogrphy 24 h after the procedure showed that the ASD device was in good position with trivival residual shunt and mild mitral regurgitation. The patient was discharged 5 days after the procedure uneventfully. One-year follow-up examinations showed that patient clinical presentations were significantly improved and NYHA class reduced to class II. ECG showed the Cocoon Septal Occluder was in good position without residual shunt, the MVA was maintained at 1.87 cm^2^ ([Fig. 3](#F3){ref-type="fig"}) and the mean pulmonary arterial pressure decreased to 19 mm Hg.

![The percutaneous mitral valvuloplasty procedure. (a) The wire crosses from right atrium to the left atrium through the ASD; (b) the Inoue balloon is introduced to the left ventricle; (c) the Inoue balloon is partly inflated and withdrawn toward mitral valve; (d) the balloon is fully expanded.](cr-09-385-g001){#F1}

![The percutaneous ASD closure procedure. (a) The sizing balloon is advanced through the superstiff wire and inflated at the atrial septum until the waist is clearly seen; (b) the device is selected and fully opened at the atrial septal defect; (c) the device after release at the anterior posterior view; (d) the device is in good position at the left anterior oblique and cranial view.](cr-09-385-g002){#F2}

![The echocardiography exam before and 12 months after procedure. (a) Mitral valve at parasternal short axis view, before mitral valvuloplasty; (b) mitral valve at parasternal short axis view, after mitral valvuloplasty; (c) the color Doppler echocardiography at parasternal short axis view shows an ASD with left to right shunt; (d) the Cocoon Septal Occluder is in good position without residual shunt.](cr-09-385-g003){#F3}

Combined percutaneous procedure for Lutembacher syndrome reported in the literature {#s2a}
-----------------------------------------------------------------------------------

There has been a serial of case reports in the lieterature about the combination of balloon mitral valvuloplasty and ASD device closure in Lutembacher syndrome ([Table 1](#T1){ref-type="table"}). Acordingly, the median of age at the time of combined procedure was 38 years old (17 - 61 years old) and most of the patients were female (87.5%). The patients commonly presented with a history of rheumatic heart disease (66.7%), dyspnea (95.8%) and palpitations (43.8%). Physical examination ussually detected diastolic murmur at apex (79.2%), fixed splitting of second heart sound (75.0%), loud first heart sound (70.8%) and systolic murmur at pulmonary area (45.8%). Most of the patients had cardiomegaly on chest radiography (91.2%) and more than haft of them had NYHA class ≥ 3 (54.2%). The most common signs found on ECG were incomplete right bundle branch block (75.0%), right atrial and/or right ventricular hypertrophy (45.8%) and atrial fibrillation (37.5%). The median of ASD size was 19 mm (13 - 30 mm); the mean MVA was 1.0 ± 0.3 cm^2^ (0.4 - 1.5 cm^2^) with the median of Wilkin score of 6.5 (5 - 8). All patients had left to right shunt through the ASD except one with bi-directional shunt \[[@R15]\].

###### Transcatheter Treatment for Lutembacher Syndrome in Literature

  Year   Author                             Age (years)   Sex      ASD size (mm)   MVA (pre/post) (cm^2^)   Balloon, dilated size   ASD device, size
  ------ ---------------------------------- ------------- -------- --------------- ------------------------ ----------------------- -----------------------
  1992   Ruiz et al \[[@R15]\]              43            Female   20              0.4/1.0                  Double balloon^a^       Lock clamshell, 40 mm
  1999   Joseph et al \[[@R16]\]            23            Female   16              1.1/2.2                  Joseph, 25 mm           Amplatzer, 16 mm
  2000   Chau et al \[[@R28]\]              26            Female   18              0.6/1.8                  Inoue, 24 mm            Amplatzer, 20 mm
  2003   Aroney et al \[[@R29]\]            61            Female   13              1.2/2.2                  Inoue, 26 mm            Amplatzer, 14 mm
  2003   Ahmed et al \[[@R19]\]             42            Female   11              1.0/1.5                  Inoue, 26 mm            Amplatzer, 17 mm
  2004   Ledesma et al \[[@R30]\]           39            Female   22              1.4/2.1                  Inoue, 26 mm            Amplatzer, 28 mm^b^
  2005   Xiang-qian et al \[[@R21]\]        61            Female   18              1.0/2.2                  Jinchang, 26 mm         Lifetech, 24 mm
  2007   Ho et al \[[@R26]\]                28            Female   18              1.5/2.4                  Inoue, 24 mm            Amplatzer, 19 mm
  2008   Shabbir et al \[[@R27]\]           17            Female   15              0.9/1.9                  Inoue, 24 mm            Amplatzer, 20 mm
  2010   Ozdemir et al \[[@R25]\]           49            Female   15              1.5/2.1                  Inoue, 28 mm            Amplatzer, 16 mm
  2011   Behjatiardakani et al \[[@R35]\]   50            Female   28              1.3/2.5                  Inoue, 26 mm            Amplatzer, 32 mm
                                            52            Female   26              1.2/2.5                  Inoue, 26 mm            Amplatzer, 32 mm
  2012   Bhambhani et al \[[@R22]\]         32            Male     19              1.0/1.9                  Inoue, 24 mm            Amplatzer, 30 mm
  2013   Malviya et al \[[@R17]\]                                  22              0.9/1.8                  Accura, 26 mm           CeraFlex, 26 mm
  2014   Babu et al \[[@R24]\]              42            Female   12              0.7/2.0                  Accura, 24 mm           Cocoon, 14 mm
  2014   Arora et al \[[@R34]\]             38            Female   22              0.9/1.8                  Inoue, 24 mm            Amplatzer, 32 mm^c^
  2014   Goel et al \[[@R32]\]              17            Female   19              0.8/2.1                  Inoue, 26 mm            Cocoon, 20 mm^d^
  2014   Thomas et al \[[@R36]\]            38            Female   26              0.7/1.9                  Inoue, 24 mm            Amplatzer, 28 mm
  2014   Vadivelu et al \[[@R18]\]          18            Male     27              0.7/1.8                  Inoue, 26mm             Heartr™, 36 mm^e^
  2015   Salam et al \[[@R03]\]             25            Female   14              1.3/3.1                  Inoue, 24 mm            Amplatzer, 18 mm
  2016   Kamana et al \[[@R13]\]            36            Female   24              1.2^f^                   Inoue, 26 mm            Cocoon, 30 mm
  2016   Datta et al \[[@R20]\]             55            Female   14              0.7/1.3                  Inoue, 25 mm            Heartr™,18 mm
  2017   Mathur et al \[[@R33]\]            18            Male     30              1.1/1.8                  Accura, 28 mm           Amplatzer, 38 mm
  2018   Phan et al                         59            Female   24              1.0/1.9                  Inoue, 24 mm            Cocoon, 26 mm

^a^15- and 20-mm valvotomy balloon catheter (Mansfield Scientific Inc.). ^b^The 24-mm Amplatzer ASD occluder was deployed first without success. ^c^The first 30-mm Amplazer device deployment was failed. ^d^ASD closure was performed 48 h after mitral valvuloplasty. ^e^The first 30-mm Amplazer device was mal-position and retrieved percutaneously. ^f^The post procedural MVA was not available.

The median of baloon cahether size for mitral valvuloplasty was 25 mm (24 - 28 mm) and the median of device size for ASD closure was 26 mm (14 - 40 mm). After the procedure, along with the increase in the MVA (1.0 ± 0.3 - 2.0 ± 0.44 cm^2^), there were also significant decreases in the mean pulmonary arterial pressure (29.2 ± 10.4 - 19.3 ± 6.1 mm Hg), mean left atrial pressure (15.6 ± 5.4 - 7.33 ± 2.65 mm Hg) and mean transmitral pressure gradient (11.9 ± 5.9 - 3.27 ± 2.2 mm Hg) ([Table 2](#T2){ref-type="table"}). Complete closure after ASD closure was seen in 91.7% of patients 24 h after the procedure and there was no residual shunt detected in all patients during follow-up. The most commonly used balloon for mitral valvularplasty was Inoue balloon (79.2%) and the most commonly used ASD closure device was Amplazer Septal Occluder (62.5%). While most of the combined procedures were performed within the same setting, in some center, the ASD closure was performed after mitral valvuloplasty 48 - 72 h to have enough time for more careful hemodynamic evaluation after the first procedure \[[@R16]\]. Besides, while ASD was used as a natural passage for mitral valvuloplasty in most procedures, some authors suggested making a low septal puncture that separated from the ASD to get more support for balloon orientating and crossing the mitral valve \[[@R17]\].

###### The Echocardiographic and Hemodynamic Changes After the Procedure

  Parameter                                  Before procedure (n = 24)   After procedure (n = 24)   P
  ------------------------------------------ --------------------------- -------------------------- ----------
  Mitral valve area (cm^2^)                  1.00 ± 0.29                 2.00 ± 0.43                \< 0.001
  Mean pulmonary arterial pressure (mm Hg)   29.2 ± 10.4                 19.3 ± 6.1                 \< 0.001
  Mean left atrial pressure (mm Hg)          15.6 ± 5.4                  7.33 ± 2.65                \< 0.001
  Mean transmitral pressure (mm Hg)          11.9 ± 5.9                  3.27 ± 2.2                 \< 0.001
  Qp/Qs\*                                    3.62 ± 1.09                 1.83 ± 0.56                \< 0.001

Qp/Qs: pulmonary/systemic blood flow ratio. \*Immediately after mitral valvuloplasty.

Major complications were rarely occurred during and after this combined procedure. In only one patient, ASD closure device malposition was detected after deployment, but the device was safely retrieved transcatheterly and another larger device was then successfully implanted \[[@R18]\]. All procedures showed insignificant mitral regurgitation after mitral balloon valvuloplasty except in one patient, mitral regurgitation degree increased from grade 2/4 to grade 3/4 without significant clinical sequence \[[@R19]\]. The sucessful procedures and favorable short- and mid-term outcome in these reports demonstrated the feasibility, safety and efficacy of the combined procedure of mitral valvuloplasty using a variety of balloon catheters and ASD closure using different device types in Lutembacher syndrome.

Discussion {#s3}
==========

Lutembacher syndrome was first described by Lutembacher in 1916, including the combination of congenital ASD and acquired MVS. In this combination, because the augmented left to right shunt of the significant ASD helps to reduce the the left atrial pressure and transmitral pressure gradient, it may delay the expression of MVS clinical symptoms \[[@R03], [@R20], [@R21]\]. However, because of the early development of severe pulmonary arterial hypertension, most of the patients will finally end up with decompensated right heart failure and other complications \[[@R22]-[@R24]\]. Even cardiac surgery is still the treatment of choice for Lutembacher syndrome, transcatheter therapy has been presented as an attractive and feasible alternative therapy \[[@R21], [@R25]-[@R30]\]. In our case, the patient and family refused to have cardiac surgery, the clinical symptoms were severe, and both MVS and ASD were suitable for transcatheter treatment, we decided to utilize this alternative therapy for the patient.

In the first combined transcatheter procedure for palliative treatment purpose in a patient with Lutembecher syndrome, severe aortic stenosis and very high pulmonary arterial pressure, Ruiz et al combined ASD closure using Lock's clamshell occluder with mitral and aortic balloon valvotomies to reduce the risk for the cardiac surgery \[[@R15]\]. However, the patient then refused cardiac surgery after the procedure and expired suddenly 8 weeks later. The first successful transcatheter procedure for Lutembecher syndrome was performed by Joseph et al in 1999, including the combination of mitral valvularplasty using Joseph balloon catheter and ASD device closure using Amplatzer Septal Occluder \[[@R16]\]. In later reports, the interventionalists used different types of devices for the two procedures ([Table 1](#T1){ref-type="table"}). In Lutembacher syndrome, although there is no risk of septal puncture because the congenital ASD can be used as the convenient passageway for mitral valvular plasty, the unstable of the Inoue balloon catheter during crossing or positioning at the mitral valve due to large ASD may make the mitral valvularplasty even more challenging \[[@R02], [@R22]\]. In these setting, if the conventional Inoue maneuver approach is unsuccessful, some alternative methods may be utilized to overcome the difficulties of mitral valve crossing such as over the wire technique, balloon floatation catheter, catheter sliding method, reverse loop method or making a large curve of the stylet \[[@R18], [@R22], [@R31]\]. In our case, the manipulation of the Inoue balloon catheter was convinient and the ASD device closure was smoothly performed. This might be due to the good ASD rims that provided adequate support for the balloon positioning and later steps \[[@R32]\].

The changes of cardiac structures regarding to the coexisting of ASD and MVS were reported to increase the risks of complications during and after the ASD closure procedure \[[@R18], [@R33]\]. Even complications during combined procedure has been rarely reported, some severe adverse events may happen during and after the procedure, including device embolization, stroke, heart block, severe mitral regurgitation, cardiac tamponade, etc. \[[@R34]\]. Some authors tended to choose undersized mitral valvuloplasty balloon catheter and oversized ASD closure device to reduce the risk of severe mitral regurgitation and device embolization \[[@R20], [@R28], [@R30], [@R32]\]. Besides, proper patient selection, careful pre-procedural assessment and operator skill improvement may be the crucial keys to prevent complications of this procedure.

In real-world practice, open heart surgery is the therapy of choice for most of the complex or combined cardiac anomalies. However, the combination of ASD and MVS in Lutembacher syndrome anatomically makes it feasible for the transcatheter therapy. In comparion with cardiac surgery, the advantages of transcatheter treatment of Lutembacher are cheaper, avoiding complications of cardiac surgery and anesthesia, faster recovery, avoiding sternotomy and skin scar, reducing psychological effect and shorter hospital stay \[[@R35], [@R36]\]. However, an important issue of this combined procedure is that the repeated trans-septal mitral valvularplasty cannot be performed again in the case of the mitral valve restenosis that may occur after the first procedure. Because the mitral valve restenosis rate after mitral valvuloplasty is quite high, the need to re-perform this procedure is also common \[[@R17], [@R33], [@R36], [@R37]\]. However, by using this combined procedure approach, the presence of ASD closure device makes it impossible for the transcatheter mitral valvularplasty using transseptal technique. Therefore, in cases with high probability of mitral restenosis after valvularplasty, cardiac surgery with valve replacement may be the best option. If the surgery cannot be selected in these cases and the right heart failure is severe even with optimal medical treament, a single palliative mitral valvularplasty procedure may be beneficial if the effect of ASD on the hemodynamic is not severe after mitral valvularplasty \[[@R32]\]. In other cases with the mitral restenosis occurring after combined procedure, the retrograde trans-arterial mitral valvuloplasty may be helpful \[[@R25], [@R35], [@R38]\]. However, in comparison with conventional mitral valvuloplasty, this technique may be more difficult and may not well be adopted by every institute. Currently, there is no report about dealing with mitral valve restenosis after combined procedure of mitral valvuloplasty and ASD closure in Lutembacher syndrome.

Conclusions {#s3a}
-----------

With the development in technology and experience gaining in cardiovascular intervention, the combination of balloon mitral valvuloplasty and ASD device closure in Lutembacher syndrome is considered feasible, safe and efficacious. This therapy can be used as an effective alternative to cardiac surgery in careful selected patients. A prospective data with larger serial of patients and longer follow-up may be necessary to address the long-term outcome of this combined procedure.
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